Nurix Therapeutics Expands ATM Equity Offering Capacity

Nurix Therapeutics ( (NRIX) ) has provided an update.

On March 6, 2026, Nurix Therapeutics amended its existing equity distribution agreement with Piper Sandler, allowing the biotech company to offer and sell up to $413.65 million of its common stock through at-the-market offerings. The total includes shares already sold under earlier amendments, with the program conducted under Nurix’s automatic shelf registration and related prospectus filings with the U.S. Securities and Exchange Commission, underscoring the company’s continued use of equity markets to support its financial flexibility and growth plans.

The most recent analyst rating on (NRIX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.

Spark’s Take on NRIX Stock

According to Spark, TipRanks’ AI Analyst, NRIX is a Neutral.

The score is held back primarily by heavy losses and very large ongoing cash burn, despite a relatively solid balance sheet. Technicals are neutral-to-soft with the stock below short-term moving averages, while recent corporate updates (positive clinical progress and strengthened liquidity) provide a meaningful offset. Valuation remains difficult to support given negative earnings and no dividend data.

To see Spark’s full report on NRIX stock, click here.

More about Nurix Therapeutics

Nurix Therapeutics, Inc. is a biotechnology company focused on the discovery and development of small-molecule therapies, with its core work centered on advancing innovative drug candidates through clinical and preclinical development. The company accesses the capital markets periodically to fund its research, development, and related corporate activities through equity offerings.

Average Trading Volume: 1,345,690

Technical Sentiment Signal: Hold

Current Market Cap: $1.57B

See more insights into NRIX stock on TipRanks’ Stock Analysis page.